A Single-Institution Retrospective Study of Three-Fraction HDR Accelerated Partial Breast Irradiation
Brachytherapy · 2023
DOI: 10.1016/j.brachy.2023.02.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brachytherapy, 2023. Verfasst von Eric M Chung und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA; Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Insti…. Hauptthemen laut MEDLINE: Brachytherapy, Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Accelerated partial breast irradiation (APBI) delivered with high-dose-rate brachytherapy is a standard of care treatment typically delivered over 10 fractions. The TRIUMPH-T multi-institutional study recently demonstrated promising results using a shorter three fraction regimen, however there are limited additional published series using this regimen. Here, we report our experience and outcomes for patients treated as per the TRIUMPH-T regimen. METHODS AND MATERIALS: This study was a retrospective single-institution analysis of patients who underwent lumpectomy followed by APBI (22.5 Gy in 3 fractions delivered over 2-3 days) using a Strut Adjusted Volume Implant (SAVI) applicator between November 2016 and January 2021. Dose-volume metrics were obtained from the clinically treated plan. Chart review was performed to determine locoregional recurrence and toxicities according to CTCAE v5.0. RESULTS: Between 2016 and 2021, 31 patients were treated per the TRIUMPH-T protocol. Median followup was 31 months from completion of brachytherapy. There were no acute/late Grade 3 or higher toxicities. Cumulative late Grade 1 and 2 toxicities were seen in 58.1% and 9.7% of patients, respectively. Of note, four patients experienced locoregional recurrence: three ipsilateral breast tumor recurrences and one nodal recurrence. All three ipsilateral breast tumor recurrences occurred in patients who would be classified as "cautionary" based on ASTRO consensus guidelines due to age ≤50, lobular histology, or high grade. CONCLUSIONS: Three-fraction HDR brachytherapy APBI was well-tolerated with no grade 3 or higher toxicities and an acceptably small percentage of grade 2 toxicities. Given the small sample size, the number of recurrences suggests that attention to appropriate patient selection is necessary until more long-term followup data is available.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA; Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA.
- Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA; Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA. Electronic address: mitchell.kamrava@cshs.org.
Zitieren
APA
Chung, E. M., Nguyen, A. T., Mirhadi, A., Steers, J. M., Phillips, T., Atkins, K. M., Burnison, M., Shiao, S. L., & Kamrava, M. (2023). A Single-Institution Retrospective Study of Three-Fraction HDR Accelerated Partial Breast Irradiation. Brachytherapy. https://doi.org/10.1016/j.brachy.2023.02.006
Vancouver
Chung EM, Nguyen AT, Mirhadi A, Steers JM, Phillips T, Atkins KM, et al. A Single-Institution Retrospective Study of Three-Fraction HDR Accelerated Partial Breast Irradiation. Brachytherapy. 2023. doi:10.1016/j.brachy.2023.02.006
BibTeX
@article{Chung2023,
author = {Chung, Eric M and Nguyen, Anthony T and Mirhadi, Amin and Steers, Jennifer M and Phillips, Tiffany and Atkins, Katelyn M and Burnison, Michele and Shiao, Stephen L and Kamrava, Mitchell},
title = {A Single-Institution Retrospective Study of Three-Fraction HDR Accelerated Partial Breast Irradiation},
journal = {Brachytherapy},
year = {2023},
doi = {10.1016/j.brachy.2023.02.006}
}
EUVIMED